← Eichor
Study identifier: NCT07420582 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Antegrade Autologous Blood Reinfusion After CPB

Condition: Coronary Artery Disease  ·  Sponsor: Kocaeli City Hospital

PhaseN/A
Planned participants130
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

This prospective observational study aims to evaluate the effect of antegrade pump blood reinfusion using the crystalloid "chase" technique on postoperative transfusion requirements in adult patients undergoing cardiac surgery with cardiopulmonary bypass. At the end of cardiopulmonary bypass, blood remaining within the cardiopulmonary bypass circuit is reinfused antegradely through the arterial line using a crystalloid chase, without collection or storage. Blood remaining within the bypass circuit after surgery represents a valuable source of autologous blood, and its reinfusion may contribute to perioperative blood conservation strategies. Patients receiving antegrade pump blood reinfusion via the chase technique will be compared with those managed without reinfusion, without any intervention by the investigators. The primary outcome is postoperative blood transfusion requirement.

This description comes directly from the study's public registry record.

Talk to the study team

Yılmaz  ·  +902622252700  ·  kocaelish@saglik.gov.tr

Always discuss trial participation with your own doctor first.

Locations (1)

Kocaeli City HospitalKocaeli, Izmit, Turkey (Türkiye)Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07420582